Ratings ModivCare Inc.

Equities

MODV

US60783X1046

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
27.07 ^USD	+1.20%		-0.92%	-38.46%

May. 22	ModivCare Inc. Accepts Resignation of Anne Bailey as President of Home	CI
May. 16	ModivCare Inc. Unveils Integration Hub: Revolutionizing Access to NEMT Benefits	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company shows low valuation levels, with an enterprise value at 0.51 times its sales.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The group shows a rather high level of debt in proportion to its EBITDA.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past four months, analysts' average price target has been revised downwards significantly.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	ESG Refinitiv
MODIVCARE INC.	-38.46%	385M	C-
HCA HEALTHCARE, INC.	+24.66%	88.38B	C+
CVS HEALTH CORPORATION	-21.76%	77.56B	B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+7.75%	28.74B	C+
FRESENIUS SE & CO. KGAA	+7.37%	18.45B	A-
LABCORP HOLDINGS INC.	-13.50%	16.57B	B
NATERA, INC.	+77.51%	13.65B	C-
TENET HEALTHCARE CORPORATION	+76.96%	13.06B	C+
FRESENIUS MEDICAL CARE AG	+4.45%	12.61B	A-
DAVITA INC.	+36.67%	12.56B	B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes